Engflag

Fluconazolo ABC

Quick links to important sections

Fluconazolo ABC

Fluconazolo ABC_EN

Method of action: Antifungal Broad Spectrum

Treatment option: Balanitis, Vaginal Candidiasis, Histoplasmosis, Fungal Infection, Fungal Infection,Fingernail, Jock Itch, Immunodeficiency, Infection, Candidemia, Candidiasis,Vaginal

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluconazolo ABC

Property Description
Active ingredient Fluconazole (INN)
Form Tablets, Oral Suspension, IV Solution
Pharmacological class Triazole Antifungal Agent (Systemic)
General purpose Manages widespread fungal infections
Origin Synthetic Compound

What Type of Medicine is Fluconazolo ABC?

Fluconazolo ABC is a prescription-only medication whose single active substance, Fluconazole, is categorized as a synthetic triazole antifungal agent. This type of medicine is developed for systemic use, meaning it is intended to circulate throughout the body to fight infections caused by sensitive yeasts and other fungal organisms. Fluconazole is distinguished from earlier antifungal classes by its pharmacokinetic profile, which provides enhanced stability and improved suitability for managing deep-seated infections.

Composition, Origin, and Available Forms

The composition centers entirely on the Fluconazole molecule, a synthetic triazole compound. Fluconazole is characterized by its nearly complete oral bioavailability (over 90%), a crucial differentiating feature that allows for a consistent drug level whether the medicine is taken by mouth or administered intravenously. Fluconazolo ABC is supplied in multiple pharmaceutical preparations, including tablets for oral intake, a powder for oral suspension (beneficial for pediatric patients), and a sterile solution for intravenous use. These forms ensure the drug can be delivered effectively across diverse healthcare environments.

General Therapeutic Purpose and Function

The primary purpose of Fluconazole is to suppress the growth of fungal pathogens that cause infection. It achieves this by interfering with the vital process by which the fungus builds its cell wall, specifically by disrupting the necessary production of the compound ergosterol. The overall function of this medicine is to establish effective therapeutic concentrations across the body, which is utilized, for instance, in reducing the incidence of severe candidiasis in patients undergoing treatments like bone marrow transplantation. This confirms its role as a recognized standard for mitigating serious fungal risks in vulnerable patient populations.

What side effects are possible with Fluconazolo ABC?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Fluconazole, the active ingredient in Fluconazolo ABC, as organized and defined in government regulatory documents.

Adverse Reaction Scope

The safety profile is structured by separating adverse effects into frequency categories and grouping them by the body systems affected. These categories are derived from regulatory standards:

  • Common Reactions (occurring in ge 1/100 to < 1/10 individuals): Include general effects such as headache, nausea, vomiting, diarrhea, abdominal pain, and documented elevations of liver enzymes (ALT, AST, Alkaline Phosphatase).
  • Uncommon Reactions (occurring in ge 1/1,000 to < 1/100 individuals): Include insomnia, somnolence, dizziness, vertigo, fatigue, fever, and skin reactions like pruritus and urticaria.
  • Rare Reactions (occurring in ge 1/10,000 to < 1/1,000 individuals): Include serious events such as anaphylaxis, severe cutaneous reactions (like Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis), agranulocytosis, and hepatic failure.

Serious Adverse Reactions and Safety Constraints

Official labels highlight the potential for specific serious adverse reactions. These include rare but clinically significant effects involving the cardiovascular system, such as QT interval prolongation and Torsade de Pointes (TdP), and rare but severe hepatic failure.

The medicine is generally contraindicated in individuals with documented hypersensitivity to triazole antifungals. Safety notes specify that caution and appropriate monitoring of function are required for specific patient groups, including individuals with pre-existing hepatic impairment and those with renal impairment, due to its elimination pathway.

Overdose and Emergency Response

Overdose and When to Seek Help

Immediate medical attention should be sought in the event of any suspected overdose with Fluconazolo ABC. Overdose may result in serious manifestations requiring urgent medical intervention.

Regulatory documentation describes documented cases of accidental overdosage, with one instance involving an extremely high ingestion of 8200 mg.

Documented Overdose Symptoms

The most significant documented clinical manifestations associated with fluconazole overdosage involve the central nervous system (CNS):

  • Hallucinations
  • Paranoid behavior

These symptoms indicate a severe reaction that necessitates professional medical care. Because the available clinical data is limited to one case of extreme overdosage, any ingestion beyond the prescribed dose must be treated as a medical emergency.

Emergency Medical Management

Treatment for an overdose is symptomatic and requires supportive measures as determined by medical staff. The official prescribing information notes specific medical procedures that may be used to manage the situation and hasten the removal of the drug from the body:

  • Forced volume diuresis will increase the elimination rate of the substance.
  • A three-hour hemodialysis session is documented to decrease the plasma concentration by approximately 50%.

Do not attempt to self-manage an overdose; contact emergency services immediately.

Therapeutic Uses of Fluconazolo ABC

What Fluconazolo ABC Treats: Main Uses and Benefits

Fluconazolo ABC is commonly used to help with a range of conditions involving episodic or fluctuating manifestations, providing supportive relief when symptoms interfere with routine activities. The therapeutic use is relevant across various sites, including conditions presenting with localized discomfort and in contexts involving symptoms related to systemic imbalance.

This medication is applied in situations involving certain distressing symptoms associated with inflammatory or irritative states, addressing symptom clusters that may become intense or disruptive. It helps address symptoms in conditions that present with disruptive symptom manifestations by easing the overall symptom load.

It is applied across domains where additional symptomatic support is needed for conditions marked by increased physiological stress, and is also commonly used when short-term symptomatic assistance is needed in high-risk scenarios. This focus helps maintain a sense of stability and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Acute Discomfort The primary benefit is easing symptoms related to inflammatory or irritative states associated with acute or disruptive episodes.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Fluconazolo ABC (fluconazole) is generally eligible for use in adults and children aged 6 months and older for approved systemic and mucosal fungal infections. However, official regulatory documents define clear contraindications and required restrictions for several populations and clinical states.

Classification Population or Condition
Absolute Contraindication Known hypersensitivity to fluconazole, related azoles, or any excipients.
Absolute Contraindication Co-administration with specific drugs that prolong the QT interval and are metabolized by the CYP3A4 enzyme (e.g., cisapride, pimozide, erythromycin, quinidine, and high-dose terfenadine).
Conditional Use/Caution Patients with renal impairment ( CrCl leq 50 mL/min): requires a mandated dose adjustment for multiple-dose therapy.
Conditional Use/Caution Patients with hepatic dysfunction or pre-existing cardiac conditions (e.g., heart rhythm problems, hypokalemia) due to the risk of QT prolongation.
Highly Restricted Pregnancy: Chronic, high-dose use (400-800 mg/day) in the first trimester is generally contraindicated due to documented risk of fetal harm. Lower, single doses require a strict benefit/risk assessment.
Use Not Fully Established Infants younger than 6 months: safety and efficacy are not established for all indications/formulations.

These official eligibility constraints define populations for whom the risk of using fluconazole outweighs the therapeutic benefit or for whom the risk must be mitigated through dose modification and intense monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fluconazole is known to interact with a wide range of medicinal products, primarily due to its role as an inhibitor of certain liver enzymes. The official regulatory profile identifies several key interaction categories.

Contraindicated Combinations

Co-administration is strictly contraindicated with certain drugs that are metabolized by the CYP3A4 enzyme and are known to prolong the QT interval. This includes, but is not limited to, terfenadine (at fluconazole doses ge 400 mg/day), cisapride, astemizole, pimozide, quinidine, and erythromycin. These combinations carry a risk of serious cardiac events.

Pharmacokinetic Interactions

Fluconazole is classified as a moderate inhibitor of CYP2C9 and CYP3A4, and a strong inhibitor of CYP2C19. This inhibition can lead to significantly increased plasma concentrations of co-administered drugs that are substrates for these enzymes. Clinically important examples include:

  • Anticoagulants (e.g., warfarin): Increased risk of bleeding due to elevated plasma levels.
  • Immunosuppressants (e.g., cyclosporine, tacrolimus): Increased exposure requires close monitoring.
  • Statins (e.g., simvastatin, atorvastatin): Increased risk of muscle toxicity.
  • Sulfonylureas (e.g., glipizide): Increased risk of hypoglycemia.

Conversely, co-administration with diuretics like hydrochlorothiazide can increase Fluconazole plasma concentrations by affecting its renal clearance. The absorption of Fluconazole is not clinically affected by food intake.

Mechanism of Action

The action of Fluconazolo ABC is defined by an initiating cascade of molecular events that interfere with the essential biochemical processes of the fungal organism. The mechanism of action involves three core domains.

Targeted Enzyme Inhibition (CYP51)

The drug acts within domains involving enzyme-mediated signaling by targeting the fungal enzyme Lanosterol 14 alpha-demethylase ( CYP51). The active ingredient functions as an inhibitor, binding specifically to the Heme iron of this enzyme. This targeted molecular action engages mechanisms that regulate the early, critical steps of fungal structural synthesis.

Disruption of the Ergosterol Biosynthesis Pathway

The inhibition of CYP51 directly modifies the molecular cascade known as the ergosterol biosynthesis pathway. This prevents the production of Ergosterol, the essential stabilizing lipid (building block) of the fungal cell membrane, while simultaneously causing the accumulation of toxic precursors. This mechanism modifies early molecular steps that shape systemic physiological outcomes for the pathogen.

Fungal Cell Membrane Damage and Growth Suppression

The resulting lack of Ergosterol and the presence of toxic sterols lead to a structurally compromised, rigid, and excessively porous fungal cell membrane. This ultimate damage compromises the targeted pathways, leading to the loss of the pathogen's ability to maintain homeostasis, resulting in the suppression of fungal growth (fungistasis), which represents the primary physiological consequence of this mechanism.

Dosage and Administration Information

How to Use Fluconazolo ABC

Fluconazolo ABC is administered by two primary routes of administration: oral (capsule, tablet, or suspension) and intravenous (IV) infusion. The daily dosage and total duration of therapy are highly variable and must be prescribed exactly by a healthcare provider, as the correct use depends entirely on the specific condition being addressed.

Administration Details

Procedural Element Official Guideline
Timing in Relation to Meals May be taken with or without food.
Oral Suspension Preparation The liquid must be shaken well before each use. The dose must be accurately measured using a calibrated measuring device (not a household spoon).
IV Infusion Rate The intravenous solution must be administered as a continuous infusion into a vein at a rate not exceeding 200 mg per hour (or 10 mL per minute).
Switching Routes It is not necessary to change the daily dose when switching administration from intravenous to oral.

Dosing and Missed Doses

Dosing Schedule: Doses for adults range from a single 150 mg oral dose to multiple-week courses of 400 mg once daily. Dosing for children is calculated based on body weight in milligrams per kilogram (mg/kg). A loading dose—double the usual daily dose—may be used on the first day to achieve steady-state concentrations more rapidly.

Missed Dose Instructions: If a dose is missed, take it as soon as you remember. However, if it is almost time for your next scheduled dose, the missed dose should be skipped. Patients must not take a double dose to make up for a missed dose.

These instructions define the standardized, required protocol for the correct and accurate administration of the medicine, which is structured by its highly variable dosing regimen and specific preparation steps.

Recent Clinical Evidence

Overview of Clinical Evaluation

Research on Fluconazole has focused on three main contexts. Studies, primarily Randomized Controlled Trials (RCTs), were monitored to explore outcomes in patients with serious systemic fungal conditions. These trials examined endpoints such as microbiological clearance and measures related to patient outcomes. Separately, short-term RCTs studied the drug in localized fungal conditions, focusing on patient-reported outcomes describing perceived discomfort and clinical resolution. Finally, research explored its use as a preventative measure (prophylaxis) in highly vulnerable patient populations, tracking outcomes like the incidence of invasive fungal infection (IFI).

Evidence in Special Populations and Limitations

Research has explored how Fluconazole was observed in children and adolescents, with studies focusing on the drug activity levels studied in these groups. For specific conditions or very young ages, data for certain groups remain insufficient for a complete picture.

Areas of Research Uncertainty

The official research record contains acknowledged gaps, primarily relating to long-term outcomes. Across most indications, long-term effects are not fully established because available follow-up durations were limited. This means evidence is limited regarding the sustained durability of response. Furthermore, study results are specific to the populations studied, and data showed variability when extrapolating findings to broader patient groups. The impact of evolving fungal resistance on the outcomes related to the medicine is also a subject where research is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Fluconazolo ABC (FAQ)

Q: When is the best time to take Fluconazolo ABC?

Fluconazolo ABC may be taken with or without food. The key requirement is to take the dose consistently at the same time each day to maintain steady levels in the body, as directed by the prescribing physician.

Q: What happens if I miss a dose of Fluconazolo ABC?

If a dose is missed, patients should follow the specific guidance provided by their healthcare professional. It is important not to take two doses at the same time to make up for a missed dose, as this could increase the risk of side effects.

Q: Can I stop taking Fluconazolo ABC once my symptoms improve?

Patients should complete the full course of treatment as prescribed by their doctor, even if symptoms begin to improve quickly. Stopping treatment early may allow the infection to return or become resistant to the medication.

How should Fluconazolo ABC be stored and disposed of?

How to Store and Dispose of Fluconazolo ABC?

Official regulatory documents define strict storage and disposal requirements to maintain product integrity and ensure safety.

Mandatory Storage Conditions

Storage conditions vary by pharmaceutical form:

  • Tablets and Dry Powder: Must be stored below 30 C (86 F). Keep the medicine in its original container, which must be tightly closed.
  • Intravenous (IV) Solution: Must be stored between 20 C and 25 C (68 F and 77 F) and must be protected from freezing.
  • Reconstituted Suspension: Store between 5 C and 30 C (41 F and 86 F), and protect from freezing.

Stability and Disposal Rules

Rule Type Requirement
Stability Limit The reconstituted oral suspension must be discarded after 14 days (2 weeks).
Child Safety Keep Fluconazolo ABC and all medicines out of the sight and reach of children.
Disposal Expired or unused medicine must be disposed of according to official government guidelines to avoid environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagItaly

Equivalent of Fluconazolo ABC found in:

A-Z Index: